TODAY'S HEADLINES

Multidrug-resistant HIV drug on the horizon

After a successful phase 3 clinical trial, a breakthrough therapy to treat multidrug resistant HIV-1 is expected to launch in the United States in 2017. Read more

Novel drug reduces migraine days

Patients with migraine headache may benefit from erenumab (Amgen and Novartis), after a phase 3 study demonstrated statistically significant reductions from baseline in monthly migraine days in patients with episodic migraine. Read more

CONTINUING PHARMACY EDUCATION

Addressing unique medication adherence issues for patients with schizophrenia

This month's CE activity, "Addressing unique medication adherence issues for patients with schizophrenia," is open for pharmacists and pharmacy technicians.
The goal of this activity is to educate pharmacists and pharmacy technicians in how to best assist patients in the use of medications to treat schizophrenia.
Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More

EDITOR'S PICK

Gilead promises generic versions of new hepatitis drug

After Gilead Sciences received FDA approval for a new drug for chronic hepatitis B virus (HBV), it said low-cost, generic versions would also soon be available. Read more

November 23, 2016

Related Articles

Faster FDA approvals lead to cancer drug boom

Study assesses the best treatments to use when a migraine attack occurs